Early Treatment for COVID-19 Globally Expands Phase 3 Study

California based Vir Biotechnology, Inc. and GlaxoSmithKline plc announced on October 6, 2020, the global expansion to Phase 3 of the COMET-ICE study evaluating VIR-7831 (GSK4182136) for the early treatment of COVID-19 in patients who are at high-risk of hospitalization. Following a positive assessment of unblinded safety data from the lead-in portion of the trial by an Independent Data Monitoring Committee, the COMET-ICE registrational study will now expand globally to additional sites in North America, South America, and Europe.